CURIGLIANO, GIUSEPPE
CURIGLIANO, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
2026 B. Besse, V. Subbiah, G. Curigliano, D.W. Bowles, R.C. Doebele, A.S. Mansfield, C.S. Baik, G. De Lima Lopes, L. Paz-Ares, M.H. Taylor, D.S.W. Tan, G. Alonso, S.M. Gadgeel, G.P. Kalemkerian, S.I. Ou, A.J. Van Der Wekken, C.R. Becerra, M. Evangelist, F. Griesinger, S.V. Liu, Y. Lou, J. Mazières, J.M. Melear, M. Narang, A. Saxena, M. Thomas, S. Wang, A. Thomassen, D.H. Lee, D. Kim, J.F. Gainor
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
2026 D. Ciardiello, G. Martini, L. Boscolo Bielo, F. Pietrantonio, A. Raimondi, P. Manca, S. Pisconti, C. Nisi, G. Tortora, L. Salvatore, A. Sartore-Bianchi, S. Siena, L. Blasi, E. Ongaro, A. Zaniboni, C. Pinto, L. Antonuzzo, A. Avallone, N. Normanno, G. Santabarbara, M.G. Zampino, R. Berardi, A. Cogoni, C. Lotesoriere, T.P. Latiano, E. Maiello, N. Fazio, G. Curigliano, R. Bordonaro, T. Troiani, F. De Vita, E. Martinelli, F. Ciardiello, S. Napolitano
Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025
2026 E. Nicolò, F. Bertucci, H. Boussen, G. Curigliano, V. Fraser, L. Gerratana, S. Krishnamurthy, H.T. Le‐petross, B. Lim, F. Lynce, A. Lucci, S. Lucotti, M. Manai, S. Merajver, N. Missal, A. Nasrazadani, A. Soliman, C. Valenza, C. Van Berckelaer, S. Van Laere, W.A. Woodward, M. Cristofanilli, G. Devi
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale
2026 M. Del Re, E. Inglese, E. Bria, E.J. Blok, R.H.J. Mathijssen, G. Curigliano, R. Danesi
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 A. Botticelli, C. Cremolini, S. Scagnoli, M. Biffoni, S. Lonardi, L. Fornaro, V. Guarneri, U. De Giorgi, P.A. Ascierto, G. Blandino, G. D'Amati, M. Aglietta, P. Conte, E. Crimini, M. Ceracchi, S. Pisegna, S. Verkhovskaia, R. Bordonaro, S. Bracarda, G. Butturini, L. Del Mastro, A. Decensi, A. Fabbri, E. Fenocchio, S. Gori, G. Metro, A. Pessino, D. Pozzessere, F. Puglisi, S. Tamberi, A. Zambelli, D. Marino, E. Capoluongo, F. Cappuzzo, B. Cerbelli, G. Giannini, U. Malapelle, F. Mazzuca, M. Nuti, G. Pruneri, M. Simmaco, L. Strigari, G. Tonini, N. Martini, G. Curigliano, P. Marchetti
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
2026 S.A. Hurvitz, S. Loi, J. O'Shaughnessy, A.F.C. Okines, S.M. Tolaney, J. Sohn, C. Saura, X. Zhu, D. Cameron, T. Bachelot, E. Hamilton, G. Curigliano, A.C. Wolff, N. Harbeck, N. Masuda, L. Vahdat, K. Zaman, F. Valdes-Albini, M. Block, T. Pluard, T.J. Tan, C. Gawryletz, A. Chan, P.L. Bedard, R. Yerushalmi, B. Xu, M. Schmitt, D. Xie, V.F. Borges
Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01)
2026 C. Biagioni, D. Fimereli, A. Irrthum, A. Guerrero-Zotano, M. Piccart, D. Cameron, C. Caballero, A. Raimbault, D. Martins-Branco, D. Romagnoli, E. Agostinetto, D. Venet, A. Llinas-Bertran, J.A. Seoane, G. Zoppoli, A. Vivancos, A. Vingiani, M. Oliveira, G. Curigliano, T. Crestani, C. Sotiriou, E. Nili Gal-Yam, F.S. Hilbers, P. Aftimos, M. Benelli
Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling
2026 G. Martini, S. Napolitano, D. Ciardiello, L.B. Bielo, E. Martinelli, T. Troiani, M.G. Zampino, N. Fazio, G. Curigliano, F. Ciardiello
Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies
2026 H.N. Tan, G. Curigliano, T.A. Yap
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens
2026 H. Wildiers, V. Adam, S. O'Reilly, J. Van Cauwenberge, A. Arahmani, C.L. Arteaga, P.L. Bedard, J. Bliss, P. Boussis, E. Brain, M. Buyse, C. Caballero, D. Cameron, F. Cardoso, E. Carrasco, A. Casas, B. Chua, G. Curigliano, A. Demichele, L. Esserman, G. Floris, M.P. Goetz, T. Goulioti, B. Haibe-Kains, C. Hodgdon, M. Ignatiadis, M. Kok, D. Lacombe, B. Linderholm, S. Loi, C.J. Lord, M. Mackenzie, J. Maues, L. Meheus, J. Needham, P. Neven, H. Parsons, M. Piccart, L. Pusztai, E. Razis, S. Saji, E. Schumacher-Wulf, G.S. Sonke, T. Spanic, I.F. Tannock, A. Tutt, A. Urruticoechea, L. Van 'T Veer, I. Vaz-Luis, G. Werutsky, D. Yee, K. Zaman, C. Desmedt
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study
2026 R. Scafetta, R. Troiano, C. Gullotta, A. Guarino, C. Fiore, L. Sisca, E. Speziale, M. Donato, S. Foderaro, F. Venuti, F.A. Vilardi, V. Ricozzi, M. Iuliani, S. Simonetti, S. Cavaliere, A. Cortellini, A.L. Cesa, A. Botticelli, S. Scagnoli, S. Pisegna, C. Criscitiello, R. Pedersini, C. Sposetti, E. Tiberi, G. D'Auria, M. Vergati, M. Mazzotta, R. Caputo, A. Verrazzo, O. Garrone, F. Domati, C. Piombino, F.S.D. Lisa, L. Filomeno, T. Arcuri, F. Puce, F. Riva, M. Palleschi, M. Sirico, M. Piras, L.S. Stucci, D.D. Lisi, P. Orsaria, A. Grasso, E. Ippolito, S. Ramella, L. Visani, L. Livi, S. Gori, L. Rossi, I. Meattini, B. Tagliaferri, O. Caffo, M.V. Bonomo, I. Portarena, A. Irelli, E. Cretella, C. Porta, G. Bianchini, M.A. Fabbri, U.D. Giorgi, P. Vici, A. Toss, F. Ruatta, M.D. Laurentiis, F. Villa, R. Berardi, M. Minelli, V. Altomare, C. Vernieri, G. Curigliano, A. Chirco, S. D'Alessandro, B. Vincenzi, G. Tonini, D. Santini, F. Pantano
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
2026 N. Harbeck, S. Modi, L. Pusztai, S. Ohno, J. Wu, S. Kim, A. Yoshida, A. Fabi, X. Cao, R. Joseph, R. Li, B. Żurawski, S. Escrivá-de-Romaní, R. Meneguetti, A. Supavavej, S. Chen, Z. Liu, C. Kelly, G. Curigliano, W.F. Symmans, M. Gufran, J. Ke, A. Konpa, P. Herbolsheimer, J. Boileau
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial
2026 J. O'Shaughnessy, F. Bidard, P. Neven, M.L. Casalnuovo, P. Aftimos, C. Saura, N. Harbeck, L.A. Carey, G. Curigliano, J.A. Garcia-Saenz, M.F. Abad, L.D. Paula, Y.H. Park, O. Ozyilkan, M. Munoz, E. Barrett, S. Cao, A. Chawla, K.L. Jhaveri
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial
2026 G. Curigliano, J. O'Shaughnessy, F. Bidard, M.L. Casalnuovo, S. Kim, E. Tokunaga, P. Aftimos, C. Saura, L.A. Carey, M. Okera, E. Melo, F. Zagouri, M. Magallanes-Maciel, N. Karadurmus, S. Bahadur, R.M. Speck, X.A. Wang, K. Pradhan, J. Macey, H. Kitchen, S. Fairhurst, J. Miller, K.L. Jhaveri, N. Harbeck
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
2026 C. Saura, J. Cortés, S. Modi, S. Kim, E. Hamilton, S.A. Hurvitz, I.E. Krop, G. Curigliano, H. Iwata, S. Im, P. Herbolsheimer, M. Karnoub, A. Boran, Y. Kuwahara, A. Egorov, F. André
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
2026 F. Ligorio, L. Provenzano, G. Fotia, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, G. Mazzoli, F. Jacobs, G. Armani, C. Sposetti, C. Zurlo, A. Menichetti, G. Griguolo, V. Faso, L. Boldrini, E. Munzone, A. Marra, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus
2026 C. De Angelis, D. De Biase, L. Gerratana, G. Arpino, G. Bianchini, I. Castellano, G. Curigliano, L. Del Mastro, A. Fabi, N. Fusco, A. Gennari, V. Guarneri, C. Zamagni, A. Zambelli, U. Malapelle, F. Puglisi
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice
2026 H.S. Rugo, A. Brufsky, R.M. Layman, X. Liu, B. Li, L. Mcroy, A.B. Cohen, M. Estevez, F. Lynce, P. Cottu, M. Thill, G. Curigliano
Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database
2026 C. Aristei, M. Tomatis, A. Ponti, L. Marotti, N.M.L. Battisti, K. Leung Cheung, O.J. Hartmann, I.T. Rubio, D. Santini, F. Sardanelli, E. Senkus, P. Van Dam, G. Curigliano